Thoroughbred Financial Services LLC Acquires New Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Thoroughbred Financial Services LLC bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 636 shares of the pharmaceutical company's stock, valued at approximately $256,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of VRTX. Insigneo Advisory Services LLC lifted its position in shares of Vertex Pharmaceuticals by 5.2% in the third quarter. Insigneo Advisory Services LLC now owns 1,314 shares of the pharmaceutical company's stock worth $611,000 after buying an additional 65 shares in the last quarter. EP Wealth Advisors LLC increased its stake in Vertex Pharmaceuticals by 5.0% in the 3rd quarter. EP Wealth Advisors LLC now owns 5,153 shares of the pharmaceutical company's stock worth $2,397,000 after acquiring an additional 244 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of Vertex Pharmaceuticals by 125.0% during the 3rd quarter. National Bank of Canada FI now owns 230,498 shares of the pharmaceutical company's stock worth $107,200,000 after acquiring an additional 128,061 shares in the last quarter. iSAM Funds UK Ltd bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $489,000. Finally, World Investment Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at $24,280,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 244 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares of the company's stock, valued at approximately $30,805,286.70. This represents a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,315 shares of company stock worth $2,121,012 in the last three months. 0.20% of the stock is owned by insiders.

Remove Ads

Analysts Set New Price Targets

VRTX has been the subject of several research reports. Wells Fargo & Company lowered shares of Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research report on Thursday, January 30th. Barclays increased their price target on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the company an "equal weight" rating in a report on Tuesday, February 11th. Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and boosted their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Finally, Scotiabank increased their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the company a "sector perform" rating in a report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $509.17.

Vertex Pharmaceuticals Stock Up 1.8 %

NASDAQ VRTX traded up $8.73 during trading on Friday, reaching $484.22. 1,574,131 shares of the company's stock traded hands, compared to its average volume of 1,325,555. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market cap of $124.34 billion, a price-to-earnings ratio of -220.10, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company's 50 day simple moving average is $484.84 and its two-hundred day simple moving average is $464.27.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.